[Skip to Content]
[Skip to Content Landing]
Citations 0
Editor's Correspondence
May 26, 2003

Is Low-Molecular-Weight Heparin Safer Than Warfarin for Secondary Prevention of Venous Thromboembolism in Cancer Patients?

Author Affiliations

Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003

Arch Intern Med. 2003;163(10):1243-1244. doi:10.1001/archinte.163.10.1243-a

I read with interest the excellent recent Original Investigation by Meyer et al1 comparing LMWH and warfarin for secondary prevention of VTE in patients with cancer.

Since LMWHs are convenient and safe for initial therapy, it is only natural that they are being evaluated as an alternative to oral anticoagulants for long-term therapy in both cancer and noncancer patients, particularly in light of the high bleeding risk associated with warfarin use. However, the authors allude to the fact that long-term LMWH therapy may be safer than warfarin in patients with cancer, a point that is debatable.

First Page Preview View Large
First page PDF preview
First page PDF preview